Search

Search Constraints

You searched for: Issue Volume 24:Issue 9(2022)

Search Results

16. A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study. Issue 9 (9th June 2022)